procaterol has been researched along with Asthma in 81 studies
Procaterol: A long-acting beta-2-adrenergic receptor agonist.
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Procaterol, a selective, short-acting beta-2 adrenoceptor agonist, is effective in treating 'classical' asthma, but its efficacy for cough-variant asthma (CVA) is unknown." | 9.17 | Efficacy of procaterol combined with inhaled budesonide for treatment of cough-variant asthma. ( Bao, W; Chen, Q; Chen, Z; Lin, Y; Liu, H; Zhao, G; Zhou, X, 2013) |
| "In moderate acute asthma, nebulized procaterol and nebulized salbutamol were both effective in improving PEFR and decreasing asthma score." | 9.15 | The efficacy of nebulized procaterol versus nebulized salbutamol for the treatment of moderate acute asthma: a randomized, double-blind, parallel group study. ( Louisa, M; Mangunnegoro, H; Novariska, F; Setiawati, A; Wiyono, WH, 2011) |
| "We examined the effect of procaterol, a beta 2-adrenoceptor agonist, on skin whealing responses to histamine, platelet-activating factor (PAF), substance P, or bradykinin in eight asthmatic children in a double-blind, randomized, cross-over study." | 9.08 | Effect of procaterol, a beta 2-adrenoceptor agonist, on skin whealing response caused by inflammatory mediators in asthmatic children. ( Arakawa, H; Maeda, S; Morikawa, A; Tokuyama, K, 1995) |
| " Twenty seven patients (20 to 64 years) with acute asthma attack were given aminophylline intravenously to obtain a theophylline concentration between 10 and 20 micrograms/ml." | 9.08 | Significance of the therapeutic range of serum theophylline concentration in the treatment of an attack of bronchial asthma. ( Murata, M; Nagasawa, K; Nakahara, Y; Ohtsu, F; Suzuki, T, 1996) |
| "We evaluated the preventive effect and duration of action of disodium cromoglycate (DSCG) and procaterol nebulizer solutions on exercise-induced asthma (EIA) in 14 asthmatic patients." | 9.07 | Preventive effect and duration of action of disodium cromoglycate and procaterol on exercise-induced asthma in asthmatic children. ( Akasawa, A; Iikura, Y; Matsuda, S; Obata, T, 1993) |
| "To evaluate the effect of inhaled beta 2 adrenergic agonists on the sensitivity of airway cough receptors, the effect of inhaled procaterol on cough induced by aerosolised capsaicin, a stimulant of C fibres, was studied in patients with asthma or chronic bronchitis and in normal subjects." | 9.07 | Effect of inhaled procaterol on cough receptor sensitivity to capsaicin in patients with asthma or chronic bronchitis and in normal subjects. ( Bando, T; Fujimura, M; Kamio, Y; Kurashima, K; Matsuda, T; Sakamoto, S, 1993) |
| "The tolerability and the duration of effect of 12 micrograms of formoterol and 25 micrograms of procaterol administered via metered-dose aerosol to 12 stable asthmatic patients were evaluated in a double-blind, placebo controlled trial." | 9.07 | Prolonged bronchodilating effect of formoterol versus procaterol in bronchial asthma. ( Chetta, A; Del Donno, M; Maiocchi, G; Moretti, D; Olivieri, D; Pisi, G, 1993) |
| "The bronchodilatory activity of one beta 2-stimulation (procaterol) and one calcium antagonist (nicardipine) both recently introduced was compared in a group of chronic asthmatics in the clinical remission phase." | 9.06 | [Comparison of the bronchodilating activity of procaterol and nicardipine in chronic forms of bronchial asthma]. ( Ardizzi, A; Barberis, S; Ciotta, D; Galietti, F; Giorgis, GE; Oliaro, A, 1987) |
| "This double-blind crossover study compared the therapeutic value of bronchodilator procaterol hydrochloride at 5 micrograms per puff by aerosol inhalation using a metered-dose inhaler and at 25 micrograms by oral administration using tablets with respective inert placebos in preventing exercise-induced bronchospasm (EIB) in 10 children with bronchial asthma." | 9.06 | Prevention of exercise-induced bronchospasm in asthmatic children. Effect of aerosol and oral procaterol hydrochloride. ( Morooka, T; Nishima, S; Ota, S, 1987) |
| "Tremor, the most common side effect of ordinary doses of beta 2-agonists, was evaluated in a quantitative manner and compared to improvement in pulmonary function in respect to time of onset, duration, peak effect, and tachyphylaxis with procaterol in adults." | 9.06 | Evaluation of tremor and efficacy of oral procaterol in adult patients with asthma. ( DeJong, R; Lutz, C; Spangler, DL; Tinkelman, DG, 1990) |
| "The efficacy of procaterol, a new beta 2-selective sympathomimetic drug, was compared with that of salbutamol and placebo in a double-dummy crossover study in 20 asthmatic patients." | 9.06 | Comparison between oral procaterol and salbutamol in patients with bronchial asthma. ( Jaakkola, J; Terho, EO; Torkko, M; Tukiainen, H, 1988) |
| "The aim of the present study was to verify the effectiveness of procaterol, a recent and specific beta-2-adrenoceptor stimulant, in preventing exercise-induced asthma (EIA)." | 9.06 | A new bronchodilating agent, procaterol, in preventing exercise-induced asthma. ( Donner, CF; Fracchia, C; Ioli, F; Manini, G; Patessio, A; Spada, EL; Vecchio, C, 1986) |
| "We studied the effective site of an inhaled aerosol of procaterol, a beta 2-selective adrenergic bronchodilator, in 8 asthmatic patients whose basal lung functions are almost within the normal range in both slow vital capacity (VC) and forced expiratory volume in one second (FEV1." | 9.06 | Possible site of bronchodilation due to inhaled procaterol aerosol in asthmatic patients. ( Hida, W; Inoue, H; Nogami, H; Taguchi, O; Takishima, T, 1988) |
| "Procaterol, a new beta-2 adrenoceptor stimulant, was studied in a double-blind, placebo-controlled, cross-over trial in patients with bronchial asthma." | 9.05 | Procaterol and terbutaline in bronchial asthma. A double-blind, placebo-controlled, cross-over study. ( Dahl, R; Harving, H; Henriksen, J; Rønne, K; Schøler, P, 1985) |
| "This double-blind crossover trial evaluated the prolonged clinical effect of procaterol inhaled in a dose of 10 micrograms by nine asthmatic children with mild and stable respiratory disturbance." | 9.05 | Effect of inhaled procaterol hydrochloride in children with bronchial asthma, with particular reference to duration of effect. ( Kimura, T; Kuroume, T; Mitsuhashi, M; Morikawa, A; Tateno, K, 1985) |
| "The purpose of the present study was to investigate pharmacokinetics of procaterol in asthmatics and non-asthmatics after nebulized and oral administration in relation to doping." | 7.83 | Pharmacokinetics of nebulized and oral procaterol in asthmatic and non-asthmatic subjects in relation to doping analysis. ( Backer, V; Hemmersbach, P; Hostrup, M; Krogh, N; Rzeppa, S, 2016) |
| "We report a case of bronchial asthma attack with lactic acidosis and hypokalemia in a patient receiving high-dose inhalation of procaterol hydrochloride." | 7.74 | [Bronchial asthma attack with lactic acidosis and hypokalemia in a case receiving high dose inhalation of procaterol hydrochloride]. ( Arimura, K; Higashimoto, I; Iwakaw, J; Kawabata, T; Koreed, Y; Kubota, S; Kumamoto, T; Matsukizono, K; Matsuyama, W; Mitsuyama, H; Mizuno, K; Noma, S; Osame, M; Suetsugu, T; Taira, T; Tanoue, A, 2007) |
| "Oral administration of procaterol at a clinical dose did not augment airway responsiveness, but did reduce eosinophil inflammation." | 7.74 | Effect of procaterol, a beta(2) selective adrenergic receptor agonist, on airway inflammation and hyperresponsiveness. ( Adachi, T; Ishida, H; Nagase, H; Nakano, J; Ohta, K; Tashimo, H; Yamamura, K; Yamashita, N; Yano, T; Yoshihara, H, 2007) |
| " In this study, we measured plasma levels of procaterol, a beta2-agonist, when being inhaled through nebulizers in children with bronchial asthma to examine relationship between improvement of pulmonary function and the plasma levels." | 7.74 | [Therapy with nebulized beta2 agonists (procaterol) in asthmatic children: pulmonary function and plasma levels after inhalation]. ( Dokai, H; Kishida, M; Kuroiwa, R; Nakamura, H; Nakazato, J; Nakazono, H; Shinomiya, N; Suzuki, I, 2007) |
| "We determined changes in arterial blood gas after the inhalation of procaterol, a highly beta 2-selective and long-acting adrenergic agonist, in 11 asthmatic children." | 7.68 | Effect of procaterol on arterial blood gas in asthmatic children. ( Ilkura, Y; Masaki, T; Obata, T, 1990) |
| "We examined the changes in arterial blood gas, FEV1 and V50 after the inhalation of procaterol on 19 occasions in 16 asthmatic children." | 7.68 | [Effects of procaterol on arterial blood gas and pulmonary function in asthmatic children]. ( Iikura, Y; Masaki, T; Obata, T, 1990) |
| "8 asthmatics were studied for 2 consecutive days in order to assess the preventive effect of a new oral beta 2-sympathomimetic, procaterol hydrochloride, against exercise-induced asthma." | 7.67 | Inhibition of exercise-induced asthma by oral procaterol, a new beta 2-adrenergic drug. ( Del Bufalo, C; Fasano, L; Gunella, G, 1984) |
| "Procaterol is a new, potent, long-acting beta-2-adrenergic bronchodilator." | 6.67 | Inhaled procaterol versus salbutamol in bronchial asthma. ( Liippo, K; Silvasti, M; Tukiainen, H, 1991) |
| "5 micrograms/kg dosage may, however, be a good starting dose because it assures a reasonable risk/benefit ratio." | 6.67 | Efficacy and duration of action of oral procaterol in asthmatic children after single administration of different dosages. ( Boner, AL; Miglioranzi, P; Piacentini, G; Richelli, C; Sette, L; Zanotto, CE, 1990) |
| "Both procaterol and albuterol were highly effective in improving pulmonary function and controlling symptoms of asthma; both were well tolerated." | 6.67 | Evaluation of procaterol and albuterol (salbutamol) aerosol in the treatment of asthma. ( Mazza, JA; Reed, CE; Tashkin, DP, 1992) |
| "Procaterol was found to be an effective, well-tolerated oral bronchodilator with a long duration of action, especially at 0." | 6.66 | A placebo-controlled trial of procaterol: a new long-acting oral beta 2-agonist in bronchial asthma. ( Borgen, LA; Brandon, ML; Katz, RM; Rachelefsky, GS; Siegel, SC, 1985) |
| " Both doses of procaterol produced significantly greater improvement in PFTs at one hour and for up to seven hours after dosing compared with placebo (p less than 0." | 6.66 | Procaterol metered-dose inhaler: a multiclinic study evaluating the efficacy and safety in patients with asthma. ( Bell, T; Brandon, ML; Chervinsky, P; Kemp, JP; Reed, CE; Repsher, L; Siegel, SC; Storms, WW, 1989) |
| "For clenbuterol, the same was also observed in comparison with placebo, while for procaterol this was true only for FEV1 and FEF25-75, while no difference resulted from FVC and PEF." | 6.66 | Oral clenbuterol and procaterol. A double-blind comparison of bronchodilator effects in children with chronic asthma. ( Boner, AL; Castellani, C; Schiassi, M; Sette, L, 1987) |
| "We examined the effects of two year's treatment of three inhaled beta 2-agonists (beta 2), such as salbutamol (S), procaterol (P) and fenoterol (F) on acetylcholine induced bronchial hyperresponsiveness (BHR) in mild approximately moderate asthmatics." | 6.18 | [Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics]. ( Ogawa, C; Sano, Y, 1996) |
| "Histamine challenges were performed before and an average of 5 months after the consecutive treatment." | 5.29 | Bronchial hyperresponsiveness changes after 5 months of regular procaterol inhalation therapy in asthmatic children. ( Aoki, T; Iikura, Y; Kishida, M; Saito, S; Sasamoto, A, 1993) |
| "Procaterol was administered per os (tabl." | 5.28 | [Clinical evaluation of procaterol and salbutamol in patients with bronchial asthma]. ( Kruszewski, J; Płusa, T; Zaraś, E, 1992) |
| " We conclude that procaterol and salbutamol are clinically similar with oral dosing and that the maximum effective dose of procaterol is not greater than 0." | 5.27 | A comparative study of a new selective beta 2-adrenoceptor agonist, procaterol and salbutamol in asthma. ( Counihan, HE; Crowe, MJ; O'Malley, K, 1985) |
| "Procaterol is a potent β2-agonist frequently used for the management of asthma and chronic obstructive pulmonary disease." | 5.20 | UGT1A1*28 is associated with greater decrease in serum K⁺ levels following oral intake of procaterol. ( Baba, K; Gosho, M; Nishimura, M; Okada, S; Takahashi, A; Tanaka, H; Yamaguchi, E; Yokoe, N, 2015) |
| "Procaterol, a selective, short-acting beta-2 adrenoceptor agonist, is effective in treating 'classical' asthma, but its efficacy for cough-variant asthma (CVA) is unknown." | 5.17 | Efficacy of procaterol combined with inhaled budesonide for treatment of cough-variant asthma. ( Bao, W; Chen, Q; Chen, Z; Lin, Y; Liu, H; Zhao, G; Zhou, X, 2013) |
| "In moderate acute asthma, nebulized procaterol and nebulized salbutamol were both effective in improving PEFR and decreasing asthma score." | 5.15 | The efficacy of nebulized procaterol versus nebulized salbutamol for the treatment of moderate acute asthma: a randomized, double-blind, parallel group study. ( Louisa, M; Mangunnegoro, H; Novariska, F; Setiawati, A; Wiyono, WH, 2011) |
| "We examined the effect of procaterol, a beta 2-adrenoceptor agonist, on skin whealing responses to histamine, platelet-activating factor (PAF), substance P, or bradykinin in eight asthmatic children in a double-blind, randomized, cross-over study." | 5.08 | Effect of procaterol, a beta 2-adrenoceptor agonist, on skin whealing response caused by inflammatory mediators in asthmatic children. ( Arakawa, H; Maeda, S; Morikawa, A; Tokuyama, K, 1995) |
| " Twenty seven patients (20 to 64 years) with acute asthma attack were given aminophylline intravenously to obtain a theophylline concentration between 10 and 20 micrograms/ml." | 5.08 | Significance of the therapeutic range of serum theophylline concentration in the treatment of an attack of bronchial asthma. ( Murata, M; Nagasawa, K; Nakahara, Y; Ohtsu, F; Suzuki, T, 1996) |
| "We evaluated the preventive effect and duration of action of disodium cromoglycate (DSCG) and procaterol nebulizer solutions on exercise-induced asthma (EIA) in 14 asthmatic patients." | 5.07 | Preventive effect and duration of action of disodium cromoglycate and procaterol on exercise-induced asthma in asthmatic children. ( Akasawa, A; Iikura, Y; Matsuda, S; Obata, T, 1993) |
| "The tolerability and the duration of effect of 12 micrograms of formoterol and 25 micrograms of procaterol administered via metered-dose aerosol to 12 stable asthmatic patients were evaluated in a double-blind, placebo controlled trial." | 5.07 | Prolonged bronchodilating effect of formoterol versus procaterol in bronchial asthma. ( Chetta, A; Del Donno, M; Maiocchi, G; Moretti, D; Olivieri, D; Pisi, G, 1993) |
| "To evaluate the effect of inhaled beta 2 adrenergic agonists on the sensitivity of airway cough receptors, the effect of inhaled procaterol on cough induced by aerosolised capsaicin, a stimulant of C fibres, was studied in patients with asthma or chronic bronchitis and in normal subjects." | 5.07 | Effect of inhaled procaterol on cough receptor sensitivity to capsaicin in patients with asthma or chronic bronchitis and in normal subjects. ( Bando, T; Fujimura, M; Kamio, Y; Kurashima, K; Matsuda, T; Sakamoto, S, 1993) |
| "The efficacy and safety of orally administered procaterol hydrochloride, a potent beta 2-adrenergic bronchodilator, was compared with that of albuterol in an eight-center, double-blind study conducted in 223 patients with mild to moderate, reversible bronchial airway obstruction." | 5.06 | A comparison of oral procaterol and albuterol in reversible airflow obstruction. ( Beaupre, A; Boulet, LP; Brandon, ML; Busse, WW; Chervinsky, P; Mazza, J; Petty, TL; Schoenweter, W, 1988) |
| "Tremor, the most common side effect of ordinary doses of beta 2-agonists, was evaluated in a quantitative manner and compared to improvement in pulmonary function in respect to time of onset, duration, peak effect, and tachyphylaxis with procaterol in adults." | 5.06 | Evaluation of tremor and efficacy of oral procaterol in adult patients with asthma. ( DeJong, R; Lutz, C; Spangler, DL; Tinkelman, DG, 1990) |
| "The aim of the present study was to verify the effectiveness of procaterol, a recent and specific beta-2-adrenoceptor stimulant, in preventing exercise-induced asthma (EIA)." | 5.06 | A new bronchodilating agent, procaterol, in preventing exercise-induced asthma. ( Donner, CF; Fracchia, C; Ioli, F; Manini, G; Patessio, A; Spada, EL; Vecchio, C, 1986) |
| " Second, we studied airway response to allergen inhalation before and after oral administration of a long-acting beta 2-stimulant (procaterol, 50 micrograms or 100 micrograms) or placebo in a double-blind crossover trial in six atopic asthmatic subjects." | 5.06 | New assessment of airway responsiveness. Effect of pretreatment with procaterol on allergen-induced bronchoconstriction. ( Hida, W; Inoue, H; Nogami, H; Shimizu, Y; Taguchi, O; Takishima, T, 1989) |
| "The bronchodilatory activity of one beta 2-stimulation (procaterol) and one calcium antagonist (nicardipine) both recently introduced was compared in a group of chronic asthmatics in the clinical remission phase." | 5.06 | [Comparison of the bronchodilating activity of procaterol and nicardipine in chronic forms of bronchial asthma]. ( Ardizzi, A; Barberis, S; Ciotta, D; Galietti, F; Giorgis, GE; Oliaro, A, 1987) |
| "This double-blind crossover study compared the therapeutic value of bronchodilator procaterol hydrochloride at 5 micrograms per puff by aerosol inhalation using a metered-dose inhaler and at 25 micrograms by oral administration using tablets with respective inert placebos in preventing exercise-induced bronchospasm (EIB) in 10 children with bronchial asthma." | 5.06 | Prevention of exercise-induced bronchospasm in asthmatic children. Effect of aerosol and oral procaterol hydrochloride. ( Morooka, T; Nishima, S; Ota, S, 1987) |
| "We studied the effective site of an inhaled aerosol of procaterol, a beta 2-selective adrenergic bronchodilator, in 8 asthmatic patients whose basal lung functions are almost within the normal range in both slow vital capacity (VC) and forced expiratory volume in one second (FEV1." | 5.06 | Possible site of bronchodilation due to inhaled procaterol aerosol in asthmatic patients. ( Hida, W; Inoue, H; Nogami, H; Taguchi, O; Takishima, T, 1988) |
| "The efficacy of procaterol, a new beta 2-selective sympathomimetic drug, was compared with that of salbutamol and placebo in a double-dummy crossover study in 20 asthmatic patients." | 5.06 | Comparison between oral procaterol and salbutamol in patients with bronchial asthma. ( Jaakkola, J; Terho, EO; Torkko, M; Tukiainen, H, 1988) |
| "This double-blind crossover trial evaluated the prolonged clinical effect of procaterol inhaled in a dose of 10 micrograms by nine asthmatic children with mild and stable respiratory disturbance." | 5.05 | Effect of inhaled procaterol hydrochloride in children with bronchial asthma, with particular reference to duration of effect. ( Kimura, T; Kuroume, T; Mitsuhashi, M; Morikawa, A; Tateno, K, 1985) |
| "Procaterol, a new beta-2 adrenoceptor stimulant, was studied in a double-blind, placebo-controlled, cross-over trial in patients with bronchial asthma." | 5.05 | Procaterol and terbutaline in bronchial asthma. A double-blind, placebo-controlled, cross-over study. ( Dahl, R; Harving, H; Henriksen, J; Rønne, K; Schøler, P, 1985) |
| "The purpose of the present study was to investigate pharmacokinetics of procaterol in asthmatics and non-asthmatics after nebulized and oral administration in relation to doping." | 3.83 | Pharmacokinetics of nebulized and oral procaterol in asthmatic and non-asthmatic subjects in relation to doping analysis. ( Backer, V; Hemmersbach, P; Hostrup, M; Krogh, N; Rzeppa, S, 2016) |
| "Given the results of this study which indicated that procaterol exerted an additive action on the anti-inflammatory effect of budesonide, procaterol and glucocorticoids may provide better control for asthma when used together than when used separately." | 3.75 | Procaterol potentiates the anti-inflammatory activity of budesonide on eosinophil adhesion to lung fibroblasts. ( Ikezono, K; Kamata, M; Mori, T; Muraguchi, M; Yoshida, N, 2009) |
| "We report a case of bronchial asthma attack with lactic acidosis and hypokalemia in a patient receiving high-dose inhalation of procaterol hydrochloride." | 3.74 | [Bronchial asthma attack with lactic acidosis and hypokalemia in a case receiving high dose inhalation of procaterol hydrochloride]. ( Arimura, K; Higashimoto, I; Iwakaw, J; Kawabata, T; Koreed, Y; Kubota, S; Kumamoto, T; Matsukizono, K; Matsuyama, W; Mitsuyama, H; Mizuno, K; Noma, S; Osame, M; Suetsugu, T; Taira, T; Tanoue, A, 2007) |
| " His chest pain improved with procaterol hydrochloride, he was diagnosed as having chest pain variant asthma." | 3.74 | [Case of chest pain variant asthma]. ( Abo, H; Imanishi, S; Izumi, S; Kanbara, K; Taniguchi, H, 2008) |
| " In this study, we measured plasma levels of procaterol, a beta2-agonist, when being inhaled through nebulizers in children with bronchial asthma to examine relationship between improvement of pulmonary function and the plasma levels." | 3.74 | [Therapy with nebulized beta2 agonists (procaterol) in asthmatic children: pulmonary function and plasma levels after inhalation]. ( Dokai, H; Kishida, M; Kuroiwa, R; Nakamura, H; Nakazato, J; Nakazono, H; Shinomiya, N; Suzuki, I, 2007) |
| "Oral administration of procaterol at a clinical dose did not augment airway responsiveness, but did reduce eosinophil inflammation." | 3.74 | Effect of procaterol, a beta(2) selective adrenergic receptor agonist, on airway inflammation and hyperresponsiveness. ( Adachi, T; Ishida, H; Nagase, H; Nakano, J; Ohta, K; Tashimo, H; Yamamura, K; Yamashita, N; Yano, T; Yoshihara, H, 2007) |
| "To evaluate the safety and usefulness of the nebulizer, we measured changes in heart rates and lung functions of 73 asthmatic children when they inhaled 1 microg/kg of procaterol with eMotion or a conventional nebulizer, Junior BOY." | 3.73 | Safety and usefulness of a novel eMotion electric mesh nebulizer in children with asthma. ( Adachi, Y; Fuchizawa, T; Itazawa, T; Ito, Y; Miyawaki, T; Murakami, G; Nakabayashi, M; Okabe, Y; Saeki Adachi, Y, 2006) |
| " We examined whether beta2-agonists altered cytokine production and cyclic adenosine monophosphate (cAMP) accumulation in concanavalin A (ConA)-activated peripheral T cells from asthmatic patients." | 3.70 | Effect of beta-agonists on production of cytokines by activated T cells obtained from asthmatic patients and normal subjects. ( Aihara, M; Araki, T; Dobashi, K; Horie, T; Iizuka, K; Mori, M; Nakazawa, T; Yoshii, A, 1999) |
| "We determined changes in arterial blood gas after the inhalation of procaterol, a highly beta 2-selective and long-acting adrenergic agonist, in 11 asthmatic children." | 3.68 | Effect of procaterol on arterial blood gas in asthmatic children. ( Ilkura, Y; Masaki, T; Obata, T, 1990) |
| "We examined the changes in arterial blood gas, FEV1 and V50 after the inhalation of procaterol on 19 occasions in 16 asthmatic children." | 3.68 | [Effects of procaterol on arterial blood gas and pulmonary function in asthmatic children]. ( Iikura, Y; Masaki, T; Obata, T, 1990) |
| "The bronchodilating effects of 5 different beta-adrenergic stimulants, isoproterenol, salbutamol, trimetoquinol, orciprenaline and procaterol were examined in 28 same patients who were in a free period from asthmatic attack." | 3.68 | [Comparison of the bronchodilating effects of five beta-adrenergic stimulants administered by inhalation to patients with bronchial asthma]. ( Kokubu, H, 1993) |
| "8 asthmatics were studied for 2 consecutive days in order to assess the preventive effect of a new oral beta 2-sympathomimetic, procaterol hydrochloride, against exercise-induced asthma." | 3.67 | Inhibition of exercise-induced asthma by oral procaterol, a new beta 2-adrenergic drug. ( Del Bufalo, C; Fasano, L; Gunella, G, 1984) |
| "Both procaterol and albuterol were highly effective in improving pulmonary function and controlling symptoms of asthma; both were well tolerated." | 2.67 | Evaluation of procaterol and albuterol (salbutamol) aerosol in the treatment of asthma. ( Mazza, JA; Reed, CE; Tashkin, DP, 1992) |
| "5 micrograms/kg dosage may, however, be a good starting dose because it assures a reasonable risk/benefit ratio." | 2.67 | Efficacy and duration of action of oral procaterol in asthmatic children after single administration of different dosages. ( Boner, AL; Miglioranzi, P; Piacentini, G; Richelli, C; Sette, L; Zanotto, CE, 1990) |
| "Procaterol is a new, potent, long-acting beta-2-adrenergic bronchodilator." | 2.67 | Inhaled procaterol versus salbutamol in bronchial asthma. ( Liippo, K; Silvasti, M; Tukiainen, H, 1991) |
| "Procaterol was found to be an effective, well-tolerated oral bronchodilator with a long duration of action, especially at 0." | 2.66 | A placebo-controlled trial of procaterol: a new long-acting oral beta 2-agonist in bronchial asthma. ( Borgen, LA; Brandon, ML; Katz, RM; Rachelefsky, GS; Siegel, SC, 1985) |
| "For clenbuterol, the same was also observed in comparison with placebo, while for procaterol this was true only for FEV1 and FEF25-75, while no difference resulted from FVC and PEF." | 2.66 | Oral clenbuterol and procaterol. A double-blind comparison of bronchodilator effects in children with chronic asthma. ( Boner, AL; Castellani, C; Schiassi, M; Sette, L, 1987) |
| "Histamine levels were noted to rise in patients who had a dual response of a mild to moderate nature, but did not change in patients who had severe asthma." | 2.66 | Role of chemical mediators after antigen and exercise challenge in children with asthma. ( Akazawa, A; Akimoto, K; Iikura, Y; Kisida, M; Kondou, T; Nagakura, T; Odajima, Y; Okuma, M; Walsh, GM; Yukishita, T, 1988) |
| " Both doses of procaterol produced significantly greater improvement in PFTs at one hour and for up to seven hours after dosing compared with placebo (p less than 0." | 2.66 | Procaterol metered-dose inhaler: a multiclinic study evaluating the efficacy and safety in patients with asthma. ( Bell, T; Brandon, ML; Chervinsky, P; Kemp, JP; Reed, CE; Repsher, L; Siegel, SC; Storms, WW, 1989) |
| "Procaterol was found to be an effective drug with a delayed onset of action when administered with food, but no effect on subsequent efficacy or duration of action." | 2.66 | The effect of diet on the efficacy onset and duration of action of procaterol hydrochloride tablets. ( Lutz, CN; Spangler, DL; Tinkelman, D, 1987) |
| "Procaterol treatment reduced (p less than 0." | 2.66 | The effect of procaterol treatment on beta-adrenergic bronchodilation and polymorphonuclear leukocyte responsiveness. ( Arbabian, M; Borgen, L; Busse, WW; Ruoho, A; Sharpe, G; Smith, A, 1985) |
| "Eosinophils play a crucial role in bronchial asthma." | 1.30 | Inhibitory effects of theophylline and procaterol on eosinophil function. ( Horie, S; Hossain, M; Isobe, M; Momose, T; Okubo, Y; Sekiguchi, M; Suzuki, J, 1997) |
| "Histamine challenges were performed before and an average of 5 months after the consecutive treatment." | 1.29 | Bronchial hyperresponsiveness changes after 5 months of regular procaterol inhalation therapy in asthmatic children. ( Aoki, T; Iikura, Y; Kishida, M; Saito, S; Sasamoto, A, 1993) |
| "Procaterol was administered per os (tabl." | 1.28 | [Clinical evaluation of procaterol and salbutamol in patients with bronchial asthma]. ( Kruszewski, J; Płusa, T; Zaraś, E, 1992) |
| "The effect of medication on peripheral airway obstruction was examined in cases of bronchial asthma." | 1.28 | [Peripheral airway obstruction and treatment]. ( Horie, T; Koyama, S; Majima, T; Mutoh, T; Ohmori, C; Ohtsuka, A; Yamaguchi, M, 1992) |
| " We conclude that procaterol and salbutamol are clinically similar with oral dosing and that the maximum effective dose of procaterol is not greater than 0." | 1.27 | A comparative study of a new selective beta 2-adrenoceptor agonist, procaterol and salbutamol in asthma. ( Counihan, HE; Crowe, MJ; O'Malley, K, 1985) |
| " The characteristics of the oral route are easy usage, precise dosage and assured effects." | 1.27 | Oral beta 2-selective adrenergic bronchodilators. ( Daniotti, S; Dottorini, M; Grassi, V; Schiassi, M; Tantucci, C, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (35.80) | 18.7374 |
| 1990's | 33 (40.74) | 18.2507 |
| 2000's | 9 (11.11) | 29.6817 |
| 2010's | 10 (12.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tomoko, O | 1 |
| Ishii, S | 1 |
| Bao, W | 1 |
| Chen, Q | 1 |
| Lin, Y | 1 |
| Liu, H | 1 |
| Zhao, G | 1 |
| Chen, Z | 1 |
| Zhou, X | 1 |
| Yokoe, N | 1 |
| Yamaguchi, E | 1 |
| Nishimura, M | 2 |
| Tanaka, H | 1 |
| Takahashi, A | 1 |
| Baba, K | 1 |
| Gosho, M | 1 |
| Okada, S | 1 |
| Kong, L | 2 |
| Liu, J | 1 |
| Gu, G | 1 |
| Huo, J | 1 |
| Ma, Z | 1 |
| Shao, Y | 1 |
| Sun, S | 1 |
| Yuan, Y | 1 |
| Zhu, S | 1 |
| Yao, C | 1 |
| Du, G | 1 |
| Cheng, M | 1 |
| Kang, J | 1 |
| Krogh, N | 1 |
| Backer, V | 1 |
| Rzeppa, S | 1 |
| Hemmersbach, P | 1 |
| Hostrup, M | 1 |
| Kitaguchi, Y | 1 |
| Yasuo, M | 1 |
| Hanaoka, M | 1 |
| Taniguchi, H | 3 |
| Furuse, H | 1 |
| Nakanishi, Y | 1 |
| Tsuda, T | 1 |
| Totsuka, K | 1 |
| Masaki, Y | 1 |
| Suzuki, K | 1 |
| Ishizawa, S | 1 |
| Miyazawa, H | 1 |
| Kanbara, K | 2 |
| Imanishi, S | 2 |
| Abo, H | 2 |
| Izumi, S | 2 |
| Yoshida, N | 1 |
| Muraguchi, M | 1 |
| Kamata, M | 1 |
| Ikezono, K | 1 |
| Mori, T | 1 |
| Matsuno, O | 1 |
| Ueno, K | 1 |
| Hayama, Y | 1 |
| Honda, H | 1 |
| Yamane, H | 1 |
| Saeki, Y | 1 |
| Mangunnegoro, H | 1 |
| Novariska, F | 1 |
| Wiyono, WH | 1 |
| Setiawati, A | 1 |
| Louisa, M | 1 |
| Itazawa, T | 2 |
| Adachi, Y | 2 |
| Ito, Y | 2 |
| Higuchi, O | 1 |
| Mochizuki, H | 2 |
| Shimojo, N | 1 |
| Inoue, T | 1 |
| Nishitsuji, M | 1 |
| Fujimura, M | 3 |
| Oribe, Y | 1 |
| Nakao, S | 1 |
| Saeki Adachi, Y | 1 |
| Nakabayashi, M | 1 |
| Fuchizawa, T | 1 |
| Okabe, Y | 1 |
| Murakami, G | 1 |
| Miyawaki, T | 1 |
| Noma, S | 1 |
| Kubota, S | 1 |
| Matsukizono, K | 1 |
| Tanoue, A | 1 |
| Kumamoto, T | 1 |
| Taira, T | 1 |
| Mitsuyama, H | 1 |
| Kawabata, T | 1 |
| Suetsugu, T | 1 |
| Iwakaw, J | 1 |
| Koreed, Y | 1 |
| Matsuyama, W | 1 |
| Mizuno, K | 1 |
| Higashimoto, I | 1 |
| Osame, M | 1 |
| Arimura, K | 1 |
| Tashimo, H | 1 |
| Yamashita, N | 1 |
| Ishida, H | 1 |
| Nagase, H | 1 |
| Adachi, T | 1 |
| Nakano, J | 1 |
| Yamamura, K | 1 |
| Yano, T | 1 |
| Yoshihara, H | 1 |
| Ohta, K | 1 |
| Kishida, M | 2 |
| Nakazono, H | 1 |
| Kuroiwa, R | 1 |
| Dokai, H | 1 |
| Nakazato, J | 1 |
| Nakamura, H | 2 |
| Suzuki, I | 1 |
| Shinomiya, N | 1 |
| Youngchaiyud, P | 1 |
| Del Bufalo, C | 1 |
| Fasano, L | 1 |
| Gunella, G | 1 |
| Yamada, Y | 1 |
| Kawai, T | 1 |
| Onaka, A | 1 |
| Kamo, T | 1 |
| Ajisawa, A | 1 |
| Tokuyama, K | 2 |
| Maeda, S | 1 |
| Arakawa, H | 2 |
| Morikawa, A | 3 |
| Habbick, B | 1 |
| Baker, MJ | 1 |
| McNutt, M | 1 |
| Cockcroft, DW | 1 |
| Kokubu, H | 1 |
| Hoffstein, V | 1 |
| Zamel, N | 1 |
| McClean, P | 1 |
| Chapman, KR | 1 |
| Sakamoto, S | 2 |
| Kamio, Y | 1 |
| Bando, T | 1 |
| Kurashima, K | 2 |
| Matsuda, T | 2 |
| Sasamoto, A | 1 |
| Saito, S | 1 |
| Aoki, T | 1 |
| Iikura, Y | 4 |
| Obata, T | 3 |
| Matsuda, S | 1 |
| Akasawa, A | 1 |
| Chetta, A | 1 |
| Del Donno, M | 1 |
| Maiocchi, G | 1 |
| Pisi, G | 1 |
| Moretti, D | 1 |
| Olivieri, D | 1 |
| Charoenratanakul, S | 1 |
| Kongchalalai, A | 1 |
| Nakahara, Y | 1 |
| Murata, M | 1 |
| Suzuki, T | 1 |
| Ohtsu, F | 1 |
| Nagasawa, K | 1 |
| Horikoshi, S | 1 |
| Kokubu, F | 2 |
| Adachi, M | 2 |
| Ogawa, C | 1 |
| Sano, Y | 1 |
| Yamamoto, C | 1 |
| Narita, N | 1 |
| Tamaoki, J | 1 |
| Kondo, M | 1 |
| Sakai, N | 1 |
| Nakata, J | 1 |
| Takemura, H | 1 |
| Nagai, A | 1 |
| Takizawa, T | 1 |
| Konno, K | 2 |
| Okubo, Y | 1 |
| Hossain, M | 1 |
| Horie, S | 1 |
| Momose, T | 1 |
| Suzuki, J | 1 |
| Isobe, M | 1 |
| Sekiguchi, M | 1 |
| Li, Z | 1 |
| Yu, R | 1 |
| Lü, G | 1 |
| Cui, D | 1 |
| Guo, Y | 1 |
| Mirza, ZN | 1 |
| Kato, M | 1 |
| Aihara, M | 1 |
| Dobashi, K | 1 |
| Horie, T | 2 |
| Araki, T | 1 |
| Yoshii, A | 1 |
| Iizuka, K | 1 |
| Nakazawa, T | 1 |
| Mori, M | 1 |
| Fontana, GA | 1 |
| Lavorini, F | 1 |
| Chiostri, M | 1 |
| Castellani, W | 1 |
| Boddi, V | 1 |
| Pistolesi, M | 1 |
| Small, RC | 1 |
| Chiu, P | 1 |
| Cook, SJ | 1 |
| Foster, RW | 1 |
| Isaac, L | 1 |
| Ojima, F | 1 |
| Ebihara, M | 1 |
| Shoji, T | 1 |
| Tomike, H | 1 |
| Nakagawa, Y | 1 |
| Płusa, T | 1 |
| Zaraś, E | 1 |
| Kruszewski, J | 1 |
| Shibasaki, M | 1 |
| Takeda, K | 1 |
| Sumazaki, R | 1 |
| Nogami, T | 1 |
| Takita, H | 1 |
| Takahashi, S | 1 |
| Koyama, S | 2 |
| Ohmori, C | 1 |
| Ohtsuka, A | 1 |
| Mutoh, T | 1 |
| Majima, T | 1 |
| Yamaguchi, M | 1 |
| Mazza, JA | 1 |
| Tashkin, DP | 1 |
| Reed, CE | 2 |
| Okiyama, M | 1 |
| Fujiwara, H | 1 |
| Kudo, M | 1 |
| Simizu, M | 1 |
| Maeda, M | 1 |
| Yamada, M | 1 |
| Toshimitsu, Y | 1 |
| Liippo, K | 1 |
| Silvasti, M | 1 |
| Tukiainen, H | 2 |
| Isawa, T | 1 |
| Teshima, T | 1 |
| Hirano, T | 1 |
| Anazawa, Y | 1 |
| Miki, M | 1 |
| Motomiya, M | 1 |
| Tinkelman, DG | 1 |
| DeJong, R | 1 |
| Lutz, C | 1 |
| Spangler, DL | 2 |
| Masaki, T | 2 |
| Ilkura, Y | 1 |
| Boner, AL | 2 |
| Zanotto, CE | 1 |
| Piacentini, G | 1 |
| Miglioranzi, P | 1 |
| Richelli, C | 1 |
| Sette, L | 2 |
| Crespo Notario, JA | 1 |
| Sobradillo Peña, V | 1 |
| Garnacho López, E | 1 |
| Ansola Zubiaurre, PM | 1 |
| Mazo Echániz, J | 1 |
| Takishima, T | 2 |
| Taguchi, O | 2 |
| Hida, W | 2 |
| Nogami, H | 2 |
| Shimizu, Y | 1 |
| Inoue, H | 2 |
| Storms, WW | 1 |
| Chervinsky, P | 2 |
| Bell, T | 1 |
| Kemp, JP | 2 |
| Brandon, ML | 3 |
| Siegel, SC | 2 |
| Repsher, L | 1 |
| Nishi, K | 1 |
| Saito, M | 1 |
| Miyake, Y | 1 |
| Katz, RM | 1 |
| Rachelefsky, GS | 1 |
| Borgen, LA | 1 |
| Crowe, MJ | 1 |
| Counihan, HE | 1 |
| O'Malley, K | 1 |
| Welch, MJ | 1 |
| Meltzer, EO | 1 |
| Orgel, HA | 1 |
| Arai, Y | 1 |
| Nitta, K | 1 |
| Shida, T | 1 |
| Grassi, V | 1 |
| Daniotti, S | 1 |
| Schiassi, M | 2 |
| Dottorini, M | 1 |
| Tantucci, C | 1 |
| De Candussio, G | 1 |
| Franchi, D | 1 |
| Manini, G | 2 |
| Arossa, W | 1 |
| Castello, D | 1 |
| Morin, D | 1 |
| Milot, J | 1 |
| Turcotte, H | 1 |
| Boulet, LP | 2 |
| Williams, WR | 1 |
| Kagamimori, S | 1 |
| Shimizu, T | 1 |
| Kakiuchi, H | 1 |
| Naruse, Y | 1 |
| Mitsuhashi, M | 1 |
| Kimura, T | 1 |
| Tateno, K | 1 |
| Kuroume, T | 1 |
| Dahl, R | 1 |
| Harving, H | 1 |
| Henriksen, J | 1 |
| Rønne, K | 1 |
| Schøler, P | 1 |
| Tsukioka, K | 1 |
| Ioli, F | 1 |
| Donner, CF | 1 |
| Fracchia, C | 1 |
| Patessio, A | 1 |
| Spada, EL | 1 |
| Vecchio, C | 1 |
| Lutz, CN | 1 |
| Tinkelman, D | 1 |
| Ardizzi, A | 1 |
| Barberis, S | 1 |
| Giorgis, GE | 1 |
| Oliaro, A | 1 |
| Galietti, F | 1 |
| Ciotta, D | 1 |
| Baughman, RP | 1 |
| Loudon, RG | 1 |
| Morooka, T | 1 |
| Nishima, S | 1 |
| Ota, S | 1 |
| Castellani, C | 1 |
| Nagakura, T | 1 |
| Walsh, GM | 1 |
| Akimoto, K | 1 |
| Kisida, M | 1 |
| Kondou, T | 1 |
| Odajima, Y | 1 |
| Okuma, M | 1 |
| Akazawa, A | 1 |
| Yukishita, T | 1 |
| Petty, TL | 1 |
| Busse, WW | 2 |
| Schoenweter, W | 1 |
| Beaupre, A | 1 |
| Mazza, J | 1 |
| Jaakkola, J | 1 |
| Torkko, M | 1 |
| Terho, EO | 1 |
| Sharpe, G | 1 |
| Smith, A | 1 |
| Arbabian, M | 1 |
| Borgen, L | 1 |
| Ruoho, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Oral Procaterol on Chronic Persistent Cough Following Upper Respiratory Tract Infection: Double-Blind Randomized Placebo-Controlled Trial[NCT02349919] | 74 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | |||
| Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough：A Prospective, Open Label, Randomized and Placebo-Controlled Trial[NCT02655562] | Phase 4 | 200 participants (Anticipated) | Interventional | 2016-04-30 | Suspended (stopped due to There are difficulties in recruiting patients) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for procaterol and Asthma
| Article | Year |
|---|---|
[Anti-allergic effects of beta-adrenoceptor agonists in the clinical pharmacological studies].
Topics: Adrenergic beta-Agonists; Albuterol; Anti-Allergic Agents; Asthma; Bronchi; Bronchial Hyperreactivit | 1996 |
[Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics].
Topics: Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Fenote | 1996 |
[The clinical usefulness of the combined use of inhaled beta 2-agonist and inhaled steroid in asthma].
Topics: Adrenergic beta-Agonists; Adult; Anti-Inflammatory Agents; Asthma; Beclomethasone; Controlled Clinic | 1996 |
[Variety of pharmacological action of beta agonists].
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchial Hyperreactivity; Bronchial Provocati | 1992 |
38 trials available for procaterol and Asthma
| Article | Year |
|---|---|
Efficacy of procaterol combined with inhaled budesonide for treatment of cough-variant asthma.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Asthma; Bronchodilator Agents; Budesonide; China; Comorb | 2013 |
UGT1A1*28 is associated with greater decrease in serum K⁺ levels following oral intake of procaterol.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Asthma; Bronchodilator Agents; Cytochrome P-450 CYP3A; F | 2015 |
Randomized, Multicenter Clinical Study of Tratinterol Hydrochloride Tablets for the Treatment of Bronchial Asthma.
Topics: Adult; Aniline Compounds; Asthma; Bronchodilator Agents; China; Double-Blind Method; Female; Humans; | 2015 |
The efficacy of nebulized procaterol versus nebulized salbutamol for the treatment of moderate acute asthma: a randomized, double-blind, parallel group study.
Topics: Acute Disease; Adolescent; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Asthma; Carbon Dio | 2011 |
Comparison of cardiorespiratory effects of procaterol and salbutamol in asthmatic patients.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Cardiovascular System; Clinical Tria | 1982 |
Effect of procaterol, a beta 2-adrenoceptor agonist, on skin whealing response caused by inflammatory mediators in asthmatic children.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bradykinin; Child; Cross-Over Studies; | 1995 |
Changes in pulmonary function and cross-sectional area of trachea and bronchi in asthmatics following inhalation of procaterol hydrochloride and ipratropium bromide.
Topics: Acoustics; Administration, Inhalation; Adult; Airway Resistance; Analysis of Variance; Asthma; Bronc | 1994 |
Effect of inhaled procaterol on cough receptor sensitivity to capsaicin in patients with asthma or chronic bronchitis and in normal subjects.
Topics: Administration, Inhalation; Adult; Aged; Asthma; Bronchi; Bronchitis; Bronchoconstriction; Capsaicin | 1993 |
Preventive effect and duration of action of disodium cromoglycate and procaterol on exercise-induced asthma in asthmatic children.
Topics: Administration, Inhalation; Adolescent; Asthma; Asthma, Exercise-Induced; Child; Cromolyn Sodium; Ex | 1993 |
Prolonged bronchodilating effect of formoterol versus procaterol in bronchial asthma.
Topics: Adolescent; Adult; Aerosols; Aged; Airway Obstruction; Asthma; Blood Pressure; Bronchodilator Agents | 1993 |
Effect of paper spacer (spader) in conjunction with procaterol metered dose inhaler in the treatment of acute asthma.
Topics: Acute Disease; Adolescent; Adult; Asthma; Bronchodilator Agents; Cross-Over Studies; Dose-Response R | 1996 |
Significance of the therapeutic range of serum theophylline concentration in the treatment of an attack of bronchial asthma.
Topics: Adrenergic beta-Agonists; Adult; Aminophylline; Asthma; Bronchodilator Agents; Female; Humans; Hydro | 1996 |
[Long-term effects of inhaled beta 2-agonists on bronchial hyperresponsiveness in asthmatics].
Topics: Administration, Oral; Adrenergic beta-Agonists; Albuterol; Asthma; Bronchial Hyperreactivity; Fenote | 1996 |
Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Anti-Asthmatic Agents; Asthma; Beclomethasone; | 1997 |
Large and small airway responses to procaterol hydrochloride administered through different extension devices in asthmatic patients.
Topics: Administration, Inhalation; Adolescent; Adult; Analysis of Variance; Asthma; Bronchi; Bronchodilator | 1999 |
Evaluation of procaterol and albuterol (salbutamol) aerosol in the treatment of asthma.
Topics: Adolescent; Adult; Aged; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Child; Dose-R | 1992 |
Inhaled procaterol versus salbutamol in bronchial asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Albuterol; Asthma; Bronchodilator Agents; Ethan | 1991 |
Evaluation of tremor and efficacy of oral procaterol in adult patients with asthma.
Topics: Administration, Oral; Adrenergic beta-Agonists; Adult; Asthma; Clinical Trials as Topic; Dose-Respon | 1990 |
Efficacy and duration of action of oral procaterol in asthmatic children after single administration of different dosages.
Topics: Administration, Oral; Asthma; Bronchodilator Agents; Child; Dose-Response Relationship, Drug; Drug A | 1990 |
[Comparative study of procaterol and salbutamol in single inhaled doses].
Topics: Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Ethanolamines; Female; Humans; Lung Volum | 1989 |
New assessment of airway responsiveness. Effect of pretreatment with procaterol on allergen-induced bronchoconstriction.
Topics: Adult; Airway Resistance; Allergens; Asthma; Bronchial Provocation Tests; Bronchial Spasm; Bronchodi | 1989 |
Procaterol metered-dose inhaler: a multiclinic study evaluating the efficacy and safety in patients with asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aerosols; Aged; Asthma; Child; Clinical Trials as Topic | 1989 |
A placebo-controlled trial of procaterol: a new long-acting oral beta 2-agonist in bronchial asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Asthma; Bronchodilator Agents; Clinical Trials as Topic | 1985 |
Therapeutic efficacy and equivalence of tablet and syrup formulations of procaterol hydrochloride in childhood asthma.
Topics: Adrenergic beta-Agonists; Asthma; Bronchodilator Agents; Child; Double-Blind Method; Drug Administra | 1985 |
Duration of oral procaterol protection from methacholine-induced bronchial obstruction.
Topics: Adrenergic beta-Agonists; Airway Resistance; Albuterol; Asthma; Child; Ethanolamines; Female; Humans | 1986 |
Effect of inhaled procaterol hydrochloride in children with bronchial asthma, with particular reference to duration of effect.
Topics: Adolescent; Aerosols; Asthma; Blood Pressure; Child; Clinical Trials as Topic; Double-Blind Method; | 1985 |
Procaterol and terbutaline in bronchial asthma. A double-blind, placebo-controlled, cross-over study.
Topics: Adolescent; Adult; Aged; Asthma; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Femal | 1985 |
A new bronchodilating agent, procaterol, in preventing exercise-induced asthma.
Topics: Adolescent; Adult; Albuterol; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents; Child; Ethano | 1986 |
The effect of diet on the efficacy onset and duration of action of procaterol hydrochloride tablets.
Topics: Adolescent; Adult; Asthma; Dietary Fats; Drug Evaluation; Ethanolamines; Fasting; Female; Forced Exp | 1987 |
[Comparison of the bronchodilating activity of procaterol and nicardipine in chronic forms of bronchial asthma].
Topics: Adult; Asthma; Bronchodilator Agents; Chronic Disease; Double-Blind Method; Ethanolamines; Female; H | 1987 |
The utility of a long-acting sympathomimetic agent, procaterol, for nocturnal asthma.
Topics: Asthma; Bronchodilator Agents; Circadian Rhythm; Delayed-Action Preparations; Ethanolamines; Humans; | 1988 |
Prevention of exercise-induced bronchospasm in asthmatic children. Effect of aerosol and oral procaterol hydrochloride.
Topics: Administration, Oral; Aerosols; Asthma; Asthma, Exercise-Induced; Bronchodilator Agents; Child; Doub | 1987 |
Oral clenbuterol and procaterol. A double-blind comparison of bronchodilator effects in children with chronic asthma.
Topics: Administration, Oral; Asthma; Bronchodilator Agents; Child; Clenbuterol; Double-Blind Method; Ethano | 1987 |
Role of chemical mediators after antigen and exercise challenge in children with asthma.
Topics: Adolescent; Animals; Asthma; Bronchial Provocation Tests; Chemotactic Factors; Child; Cromolyn Sodiu | 1988 |
A comparison of oral procaterol and albuterol in reversible airflow obstruction.
Topics: Administration, Oral; Airway Obstruction; Albuterol; Asthma; Bronchodilator Agents; Clinical Trials | 1988 |
Possible site of bronchodilation due to inhaled procaterol aerosol in asthmatic patients.
Topics: Adult; Aerosols; Airway Resistance; Asthma; Bronchodilator Agents; Ethanolamines; Female; Humans; Ma | 1988 |
Comparison between oral procaterol and salbutamol in patients with bronchial asthma.
Topics: Administration, Oral; Adult; Albuterol; Asthma; Clinical Trials as Topic; Double-Blind Method; Drug | 1988 |
The effect of procaterol treatment on beta-adrenergic bronchodilation and polymorphonuclear leukocyte responsiveness.
Topics: Adult; Asthma; Bronchodilator Agents; Cyclic AMP; Dose-Response Relationship, Drug; Double-Blind Met | 1985 |
40 other studies available for procaterol and Asthma
| Article | Year |
|---|---|
Inhalational β
Topics: Acidosis, Lactic; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Anti-Asthmatic Ag | 2019 |
Pharmacokinetics of nebulized and oral procaterol in asthmatic and non-asthmatic subjects in relation to doping analysis.
Topics: Administration, Inhalation; Administration, Oral; Adrenergic beta-2 Receptor Agonists; Asthma; Chrom | 2016 |
Comparison of pulmonary function in patients with COPD, asthma-COPD overlap syndrome, and asthma with airflow limitation.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Airway Resistance; Asthma; Br | 2016 |
Bronchial biopsy and reactivity in patients with chest tightness relieved with bronchodilator.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Airway Obstruction; As | 2017 |
[A case of smoking-induced chest pain improved with beta2-stimulant].
Topics: Adrenergic beta-Agonists; Adult; Asthma; Chest Pain; Humans; Male; Procaterol; Smoking | 2008 |
Procaterol potentiates the anti-inflammatory activity of budesonide on eosinophil adhesion to lung fibroblasts.
Topics: Anti-Inflammatory Agents; Asthma; Budesonide; Cell Adhesion; Cell Line; Chemokine CCL11; Dose-Respon | 2009 |
Deterioration of asthma in a patient with diffuse panbronchiolitis (DPB) after macrolide therapy.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Asthma; Bronchiolitis; Clarithromycin; F | 2010 |
Aerosol characteristics of admixture of budesonide inhalation suspension with a beta2-agonist, procaterol.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aerosols; Asthma; Bronchodilator Ag | 2013 |
A guinea pig model for cough variant asthma and role of tachykinins.
Topics: Airway Resistance; Allergens; Animals; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lavage F | 2004 |
Safety and usefulness of a novel eMotion electric mesh nebulizer in children with asthma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Asthma; Child; Child, Preschool; Drug Administ | 2006 |
[Bronchial asthma attack with lactic acidosis and hypokalemia in a case receiving high dose inhalation of procaterol hydrochloride].
Topics: Acidosis, Lactic; Administration, Inhalation; Adrenergic beta-Agonists; Adult; Asthma; Humans; Hypok | 2007 |
Effect of procaterol, a beta(2) selective adrenergic receptor agonist, on airway inflammation and hyperresponsiveness.
Topics: Adrenergic beta-Agonists; Airway Resistance; Animals; Asthma; Bronchial Hyperreactivity; Bronchoalve | 2007 |
[Therapy with nebulized beta2 agonists (procaterol) in asthmatic children: pulmonary function and plasma levels after inhalation].
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonist | 2007 |
[Case of chest pain variant asthma].
Topics: Acetates; Adult; Androstadienes; Asthma; Chest Pain; Cyclopropanes; Drug Therapy, Combination; Fluti | 2008 |
Inhibition of exercise-induced asthma by oral procaterol, a new beta 2-adrenergic drug.
Topics: Adolescent; Adult; Asthma; Asthma, Exercise-Induced; Bronchial Spasm; Chemical Phenomena; Chemistry; | 1984 |
[Influence of sympathomimetic drugs on immediate intradermal reactions induced by allergens].
Topics: Adult; Albuterol; Asthma; Clenbuterol; Ethanolamines; Humans; Hypersensitivity, Immediate; Intraderm | 1984 |
Recent trends in the use of inhaled beta 2-adrenergic agonists and inhaled corticosteroids in Saskatchewan.
Topics: Administration, Inhalation; Administration, Topical; Adolescent; Adrenergic beta-Agonists; Adult; Ae | 1995 |
[Comparison of the bronchodilating effects of five beta-adrenergic stimulants administered by inhalation to patients with bronchial asthma].
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchoc | 1993 |
Bronchial hyperresponsiveness changes after 5 months of regular procaterol inhalation therapy in asthmatic children.
Topics: Administration, Inhalation; Adolescent; Aerosols; Asthma; Bronchial Hyperreactivity; Bronchial Provo | 1993 |
Inhibitory effects of theophylline and procaterol on eosinophil function.
Topics: Asthma; Bronchodilator Agents; CD11 Antigens; CD18 Antigens; Cell Adhesion Molecules; Cell Degranula | 1997 |
[The effect of salmeterol on the activity of neutrophil chemotactic factor in patients with asthma].
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Female; Humans; Interleukin-8; Male; Middle Aged | 1996 |
[The changes of glucocorticoid receptor and beta-adrenoreceptor of lung tissues in SD rat asthma models and the effects of antiasthmatics on them].
Topics: Adrenergic beta-Agonists; Animals; Asthma; Dexamethasone; Glucocorticoids; Lung; Male; Procaterol; R | 1996 |
Inhaled procaterol inhibits histamine-induced airflow obstruction and microvascular leakage in guinea-pig airways with allergic inflammation.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Airway Resistance; Animals; Asthma; Bronchi; C | 1998 |
Effect of beta-agonists on production of cytokines by activated T cells obtained from asthmatic patients and normal subjects.
Topics: Adrenergic beta-Agonists; Asthma; Cells, Cultured; Concanavalin A; Cyclic AMP; Humans; Interleukin-2 | 1999 |
Beta-adrenoceptor agonists in bronchial asthma: role of k+-channel opening in mediating their bronchodilator effects.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 1993 |
Clinical characteristics of asthmatic patients prescribed various beta-agonist metered-dose inhalers at Yamagata University Hospital.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Ch | 2001 |
[Clinical evaluation of procaterol and salbutamol in patients with bronchial asthma].
Topics: Adolescent; Adult; Albuterol; Asthma; Child; Female; Humans; Male; Middle Aged; Procaterol | 1992 |
Premenstrual asthma with seasonal variation.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Allergens; Animals; Antibodies; Antigen | 1992 |
[Peripheral airway obstruction and treatment].
Topics: Administration, Inhalation; Airway Obstruction; Animals; Asthma; Asthma, Exercise-Induced; Beclometh | 1992 |
[Pharmacological action of SN-408, a novel long-acting selective beta 2-adrenoceptor agonist].
Topics: Adrenergic beta-Agonists; Albuterol; Animals; Asthma; Bronchodilator Agents; Capillary Permeability; | 1991 |
Does a beta 2-stimulator really facilitate mucociliary transport in the human lungs in vivo? A study with procaterol.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aerosols; Aged; Asthma; Bronchodilator | 1990 |
Effect of procaterol on arterial blood gas in asthmatic children.
Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Asthma; Child; Ethanolamines; Fema | 1990 |
[Effects of procaterol on arterial blood gas and pulmonary function in asthmatic children].
Topics: Administration, Inhalation; Adolescent; Asthma; Bronchodilator Agents; Child; Ethanolamines; Female; | 1990 |
[Inhibitory effect of procaterol (beta 2 agonist) on the release of cyclooxygenase products during antigen-induced bronchoconstriction in the guinea pig in vivo].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Animals; Asthma; Bronchial Provocation Tests; | 1989 |
A comparative study of a new selective beta 2-adrenoceptor agonist, procaterol and salbutamol in asthma.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Blood Pressure; Ethanolamines; Force | 1985 |
[Evaluation of procaterol aerosol as an aerosolized beta 2-adrenergic bronchodilator in conscious guinea pigs].
Topics: Adrenergic beta-Agonists; Aerosols; Albuterol; Animals; Asthma; Bronchodilator Agents; Drug Resistan | 1985 |
Oral beta 2-selective adrenergic bronchodilators.
Topics: Administration, Oral; Adrenergic beta-Agonists; Aged; Asthma; Bronchodilator Agents; Child; Clenbute | 1986 |
[A new aerosol adrenergic bronchodilator, procaterol. Comparative study of salbutamol and procaterol].
Topics: Adrenergic beta-Agonists; Adult; Aerosols; Albuterol; Asthma; Bronchodilator Agents; Double-Blind Me | 1987 |
Effects of theophylline, beta-adrenergic stimulants and prednisolone on platelet and urine cyclic guanosine monophosphate (cGMP).
Topics: Adrenergic beta-Agonists; Adult; Aged; Albuterol; Aminophylline; Asthma; Blood Platelets; Cyclic GMP | 1988 |
[Bronchodilating effects of procaterol and aminophylline alone and in combination in asthmatic patients].
Topics: Adult; Aminophylline; Asthma; Drug Therapy, Combination; Ethanolamines; Female; Humans; Male; Middle | 1985 |